Stock 6242 LI KANG BIOMEDICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Li Kang Biomedical Co., Ltd.

Equities

6242

TW0006242001

Food Processing

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
50.7 TWD -0.39% Intraday chart for Li Kang Biomedical Co., Ltd. +0.40% -13.04%
May. 10 Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 13 Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 967.9 893.5 823.6 872.5 1,315 1,563
Enterprise Value (EV) 1 861.4 748.8 644 730.2 1,051 1,353
P/E ratio 12.7 x 12.5 x 12 x 17 x 11.8 x 14.2 x
Yield 5.73% 4.97% 7.55% 3.82% 3.55% -
Capitalization / Revenue 1.95 x 1.85 x 1.8 x 2.25 x 1.92 x 2.48 x
EV / Revenue 1.74 x 1.55 x 1.41 x 1.89 x 1.54 x 2.15 x
EV / EBITDA 7.88 x 7.06 x 6.71 x 10.4 x 7.09 x 9.32 x
EV / FCF 421 x 9.81 x 10.7 x 18.1 x 8.23 x 19.3 x
FCF Yield 0.24% 10.2% 9.39% 5.53% 12.1% 5.18%
Price to Book 2.07 x 1.85 x 1.62 x 1.77 x 2.31 x 2.48 x
Nbr of stocks (in thousands) 26,807 26,807 26,807 26,807 26,807 26,807
Reference price 2 36.11 33.33 30.72 32.55 49.04 58.30
Announcement Date 3/25/19 3/25/20 3/15/21 3/21/22 3/13/23 3/13/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 495.6 483.3 456.7 387 684.3 629.4
EBITDA 1 109.3 106.1 95.94 70.14 148.3 145.1
EBIT 1 91 88.31 80.93 57.24 137.4 133.4
Operating Margin 18.36% 18.27% 17.72% 14.79% 20.07% 21.19%
Earnings before Tax (EBT) 1 96.27 91.33 86.94 63.48 140.8 139.1
Net income 1 76.74 72.02 69.27 51.44 112.1 111
Net margin 15.48% 14.9% 15.17% 13.29% 16.38% 17.64%
EPS 2 2.841 2.667 2.567 1.913 4.156 4.120
Free Cash Flow 1 2.044 76.35 60.46 40.35 127.7 70.08
FCF margin 0.41% 15.8% 13.24% 10.43% 18.67% 11.14%
FCF Conversion (EBITDA) 1.87% 71.98% 63.02% 57.54% 86.1% 48.3%
FCF Conversion (Net income) 2.66% 106.02% 87.29% 78.45% 113.95% 63.14%
Dividend per Share 2 2.070 1.656 2.319 1.242 1.739 -
Announcement Date 3/25/19 3/25/20 3/15/21 3/21/22 3/13/23 3/13/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 107 145 180 142 263 210
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 2.04 76.4 60.5 40.4 128 70.1
ROE (net income / shareholders' equity) 16.8% 15.2% 14% 10.3% 21.1% 18.5%
ROA (Net income/ Total Assets) 9.43% 8.93% 7.96% 5.68% 13.2% 11%
Assets 1 813.5 806.6 870.5 906.3 851.9 1,009
Book Value Per Share 2 17.40 18.00 19.00 18.40 21.30 23.50
Cash Flow per Share 2 6.140 5.300 3.660 3.780 4.920 4.170
Capex 1 77.3 0.15 1.77 4.25 1.16 3.26
Capex / Sales 15.61% 0.03% 0.39% 1.1% 0.17% 0.52%
Announcement Date 3/25/19 3/25/20 3/15/21 3/21/22 3/13/23 3/13/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Special Foods & Wellbeing Products

1st Jan change Capi.
LI KANG BIOMEDICAL CO., LTD. Stock Li Kang Biomedical Co., Ltd.
-13.04% 49.93M
ZHEJIANG NHU COMPANY LTD. Stock Zhejiang NHU Company Ltd.
+15.92% 8.35B
BELLRING BRANDS, INC. Stock BellRing Brands, Inc.
+3.37% 7.62B
CSPC INNOVATION PHARMACEUTICAL CO., LTD. Stock CSPC Innovation Pharmaceutical Co., Ltd.
+1.49% 6.01B
THE SIMPLY GOOD FOODS COMPANY Stock The Simply Good Foods Company
-5.33% 3.75B
BYHEALTH CO., LTD Stock Byhealth Co., Ltd
-7.57% 3.7B
XIAMEN KINGDOMWAY GROUP COMPANY Stock Xiamen Kingdomway Group Company
-2.94% 1.34B
HERBALIFE LTD. Stock Herbalife Ltd.
-26.08% 1.13B
SIRIO PHARMA CO., LTD. Stock Sirio Pharma Co., Ltd.
+14.95% 992M
USANA HEALTH SCIENCES, INC. Stock USANA Health Sciences, Inc.
-9.40% 925M
Special Foods & Wellbeing Products
  1. Stock Market
  2. Equities
  3. 6242 Stock
  4. Financials Li Kang Biomedical Co., Ltd.